Immunovant, Inc. – NASDAQ:IMVT

Add to watchlist

$14.82

-9.66

-39.49%

Market closed

Open in about 12 hours

-19.89%

month

-19.89%

quarter

-43.78%

year

Market Cap	3.79B
Enterprise value	1.45B

P/E	-8.72
EV/Sales	N/A
EV/EBITDA	-7.50
Price/Sales	N/A
Price/Book	4.54
PEG ratio	0.50
EPS	-1.74

Revenue	N/A
EBITDA	-233.53M
Income	-223.30M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Immunovant, Inc. (NASDAQ:IMVT): Profit margin
Dec 2021	0	-41.38M
Mar 2022	0	-47.17M
Mar 2023	0	-59.43M
Mar 2024	0	-75.31M

Immunovant Financials Estimate

Q Y

Immunovant, Inc. (NASDAQ:IMVT): Analyst Estimates
Sep 2025	0	-94.66M
Oct 2025	0	-95.20M
Dec 2025	0	-95.93M
Mar 2026	0	-98.99M

Analysts Price target
Financials & Ratios estimates

Immunovant, Inc. (NASDAQ:IMVT): Debt to assets
Sep 2022	428146000	32.39M	7.57%
Dec 2022	456243000	41.56M	9.11%
Mar 2023	405838000	43.34M	10.68%
Mar 2024	666712000	48.95M	7.34%

Immunovant, Inc. (NASDAQ:IMVT): Cash Flow
Dec 2021	-31.89M	-74K	0
Mar 2022	-32.95M	-118K	0
Mar 2023	-55.79M	-26K	233K
Mar 2024	-59.69M	-150K	1.54M

Immunovant alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Immunovant, Inc. (NASDAQ:IMVT): Employee count
Sep 2023	164
Oct 2023	164
Nov 2023	164
Dec 2023	164
Jan 2024	164
Feb 2024	164
Mar 2024	164
Apr 2024	164
May 2024	164
Jun 2024	164
Jul 2024	207

Immunovant
Hedge Funds Holdings Q1 2023

12.77% -35.66%

of IMVT is owned by hedge funds

80 -51

hedge funds hold IMVT stock

16.41M -40.03M

shares is hold by hedge funds

IMVT hedge funds holdings changes

Immunovant, Inc. (NASDAQ:IMVT): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	22188
Feb 2024	0	22885
Apr 2024	0	98566
May 2024	0	29941
Jul 2024	0	41401
Aug 2024	0	28185
Oct 2024	0	38326
Nov 2024	0	27869
Dec 2024	0	13175

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Dec 2024	PANDE ATUL director director	Common Stock	7,750	$28.54	$221,185
Sale	2 Dec 2024	HUGHES DOUGLAS J. director director	Common Stock	5,425	$28.54	$154,830
Sale	20 Nov 2024	LEVINE MARK S. officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	3,650	$25.45	$92,893
Sale	20 Nov 2024	MACIAS WILLIAM L. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	3,353	$25.45	$85,334
Sale	20 Nov 2024	BARNETT EVA RENEE officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	4,174	$25.45	$106,228
Sale	20 Nov 2024	SALZMANN PETER director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	16,692	$25.45	$424,811
Sale	23 Oct 2024	LEVINE MARK S. officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	4,361	$29.53	$128,780
Sale	23 Oct 2024	GEFFNER MICHAEL officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	3,189	$29.53	$94,171
Sale	23 Oct 2024	STOUT JAY S officer: Chief Technology Officer officer: Chief Technology Officer	Common Stock	2,740	$29.53	$80,912
Sale	16 Oct 2024	SALZMANN PETER director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	9,095	$28.79	$261,845

Immunovant
Earnings Call Transcripts

Quarter	Transcript
Q4 2022 9 Jun 2022	Q4 2022 Earnings Call Transcript
Q1 2022 9 Aug 2021	Q1 2022 Earnings Call Transcript

IMVT earnings call transcripts

Immunovant
Executives

Insider	Age	Compensation
Dr. Peter Salzmann M.B.A., M.D. (1968) Chief Executive Officer & Director	57	$1,020,000
Dr. Julia G. Butchko Ph.D. (1971) Chief Devel. & Technology Officer	54	$531,000
Dr. Frank M. Torti M.B.A., M.D., MBA (1979) Executive Chairperson of the Board	46	$97,500

Immunovant
Latest News

Friday, 27 December 2024
10:50	Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study	seekingalpha.com
Wednesday, 11 December 2024
06:25	FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial	globenewswire.com
Friday, 8 November 2024
11:41	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus	zacks.com
Thursday, 7 November 2024
06:30	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024	globenewswire.com
Tuesday, 29 October 2024
06:30	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting	globenewswire.com
Monday, 9 September 2024
12:54	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?	benzinga.com
09:35	IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab	zacks.com
09:12	Top 2 Health Care Stocks That May Collapse This Quarter	benzinga.com
07:00	Roivant Provides Update on Graves' Disease Development Program	globenewswire.com
03:55	Immunovant Provides Update on Graves' Disease Development Program	globenewswire.com
Thursday, 5 September 2024
12:36	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?	zacks.com
Tuesday, 6 August 2024
08:25	Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging	seekingalpha.com
Thursday, 30 May 2024
12:31	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus	zacks.com
Wednesday, 29 May 2024
16:01	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024	globenewswire.com
09:12	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump	investors.com
Monday, 13 May 2024
10:55	Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet	Zacks Investment Research
Monday, 6 May 2024
10:51	5 Biotech Stocks Worth Adding to Your Portfolio in 2024	Zacks Investment Research
Monday, 22 April 2024
12:56	Here's Why You Should Add Immunovant (IMVT) to Your Portfolio	Zacks Investment Research
Wednesday, 17 April 2024
13:01	What Makes Immunovant (IMVT) a New Buy Stock	Zacks Investment Research
Thursday, 4 April 2024
02:12	Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)	Seeking Alpha
Monday, 25 March 2024
15:00	Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich	InvestorPlace
Thursday, 21 March 2024
09:25	Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results	Investors Business Daily
Wednesday, 13 March 2024
12:36	Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?	Zacks Investment Research
Friday, 8 March 2024
10:36	Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks	Zacks Investment Research
Tuesday, 13 February 2024
08:31	Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus	Zacks Investment Research
Tuesday, 6 February 2024
14:38	7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024	InvestorPlace
Friday, 19 January 2024
16:39	3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024	InvestorPlace
Tuesday, 9 January 2024
09:00	Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas	Seeking Alpha
Thursday, 21 December 2023
12:02	Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data	Zacks Investment Research
10:36	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off	Investors Business Daily

Ideas & Opinions

Seeking Alpha 15 Aug 2025

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Seeking Alpha 27 Dec 2024

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Seeking Alpha 28 Jun 2024

Argenx: Strong Setup For Outperformance In 2025
Seeking Alpha 28 Jun 2024

Immunovant: Overvalued Amidst M&A Speculation
Seeking Alpha 2 Jun 2024

Roivant Sciences: Executing On Huge Buyback Program With More To Come
Seeking Alpha 4 Apr 2024

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Seeking Alpha 1 Feb 2024

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Seeking Alpha 29 Dec 2023

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023
Seeking Alpha 14 Nov 2023

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
Seeking Alpha 24 Oct 2023

Roivant Sciences: Risk-Transforming Deal Met With Crickets

Frequently Asked Questions (FAQ)

What's the price of Immunovant stock today?

One share of Immunovant stock can currently be purchased for approximately $14.82.
When is Immunovant's next earnings date?

Unfortunately, Immunovant's (IMVT) next earnings date is currently unknown.
Does Immunovant pay dividends?

No, Immunovant does not pay dividends.
How much money does Immunovant make?

Immunovant has a market capitalization of 3.79B.
What is Immunovant's stock symbol?

Immunovant, Inc. is traded on the NASDAQ under the ticker symbol "IMVT".
What is Immunovant's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Immunovant?

Shares of Immunovant can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Immunovant's key executives?
Immunovant's management team includes the following people:
- Dr. Peter Salzmann M.B.A., M.D. Chief Executive Officer & Director(age: 57, pay: $1,020,000)
- Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer(age: 54, pay: $531,000)
- Dr. Frank M. Torti M.B.A., M.D., MBA Executive Chairperson of the Board(age: 46, pay: $97,500)
How many employees does Immunovant have?

As Jul 2024, Immunovant employs 207 workers, which is 26% more then previous month and 26% more then previous quarter.
When Immunovant went public?

Immunovant, Inc. is publicly traded company for more then 6 years since IPO on 21 Jun 2019.
What is Immunovant's official website?

The official website for Immunovant is immunovant.com.
Where are Immunovant's headquarters?

Immunovant is headquartered at 320 West 37th Street, New York, NY.
How can i contact Immunovant?

Immunovant's mailing address is 320 West 37th Street, New York, NY and company can be reached via phone at +91 75803099.

Immunovant, Inc.

immunovant.com

Exchange:

NASDAQ

Full time employees:

207

Industry:

Biotechnology

Sector:

Healthcare

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

+91 75803099

320 West 37th Street
New York, NY 10018

CIK: 0001764013
ISIN: US45258J1025
CUSIP: 45258J102